Recent Articles from GlobeNewswire

Live Webcast of Fireside Q&A Discussion on Monday, March 23, 2026 at 4:00 pm PT as it Nears its Full Market Release of the LIBERTY® in April

STAMFORD, Conn., March 17, 2026 (GLOBE NEWSWIRE) -- ReFocus Eye Health (“ReFocus”) today announced a strategic affiliation with a network of premier ophthalmology practices and ambulatory surgery centers across New Jersey, Pennsylvania, Maryland and New York that comprise Omni Ophthalmic Management Consultants (“OOMC”).

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

Company executives will discuss their business strategies, provide updates on recent developments, and answer questions live from investors.

FY 2025 Sales Growth of 72% to $9.7 Million Driven by Strong Demand for Battery Products, Accessories and Technologies

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Saratoga Investment Corp. (NYSE:SAR) (“Saratoga Investment” or “the Company”), a business development company, today announced that its Board of Directors has declared a base quarterly dividend of $0.75 per share in aggregate for the first quarter of fiscal 2027, paid in three monthly dividends as follows:

CEO Chris Pavlovski to Participate in Fireside Chat and 1-on-1 Investor Meetings

NEW YORK, NY, March 17, 2026 (GLOBE NEWSWIRE) -- Guardforce AI Co., Limited (“Guardforce AI” or the “Company”) (NASDAQ: GFAI, GFAIW), an AI-driven technology company providing Agentic AI smart solutions in automation, robotics, and secured logistics, today announced it has completed the acquisition of 100% of the issued share capital of MGAI Limited (“MGAI”), a Hong Kong-incorporated holding company.

HOUSTON, TEXAS, March 17, 2026 (GLOBE NEWSWIRE) -- Prairie Operating Co. (Nasdaq: PROP) (the “Company” or “Prairie”), an independent energy company engaged in the development and acquisition of oil and natural gas resources in the Denver-Julesburg (DJ) Basin – today announced it will release its fourth quarter and fiscal year 2025 financial and operating results after market close on March 31, 2026.

NEWARK, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- IDT Corporation (NYSE: IDT), a global provider of fintech and communications solutions, will present at the Sidoti Virtual Investor Conference. The conference will be held on March 18th and 19th, 2026.

Vertex available on Oracle Cloud Infrastructure enables rapid deployment and advanced global tax management

Atlanta, GA, March 17, 2026 (GLOBE NEWSWIRE) -- ScanTech AI Systems Inc. (OTCQB: STAI) ("ScanTech AI" or the "Company"), a developer of advanced AI-powered security screening and imaging technologies, today announced that its common stock has commenced quotation on the OTCQB® Venture Market, operated by OTC Markets Group Inc. The Company's shares previously traded on the OTC Pink market following the suspension of trading on the Nasdaq Global Market on February 10, 2026.

New collaboration broadens access to Clover all-in-one commerce solution and bolsters Fiserv’s regional footprint and specialized industry reach

CULVER CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, will hold a conference call and webcast on Thursday, March 19, 2026 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the fourth quarter and full year ended December 31, 2025.

New Milestone Set for Highest Number of Badges Across Key Data Protection Categories.

PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric lysosomal storage disorders (“LSDs”), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease).

Just Capital’s Annual Rankings Highlight Outstanding Corporate Performance Based on the Priorities of the American Public

This article has been disseminated on behalf of LaFleur Minerals and may include paid advertising. 

Case Study Details the Company’s Human-Led, Risk-Aligned AI Strategy Across Five Critical Domains

San Rafael, Bulacan, Philippines, March 17, 2026 (GLOBE NEWSWIRE) -- One and One Green Technologies. INC (“One and One” or the “Company”) (NASDAQ: YDDL), a Philippines-based recycler holding a government-issued license in the Philippines to import and process hazardous waste as raw materials, today announced its plan to strategically enter into the Greater Manila Area’s electronic waste (e-waste) resource recovery market. Leveraging its 1,000,000-ton-per-year hazardous waste treatment permit, the Company will source and process high-value industrial materials, including electronic sludge, copper mud, and nickel mud, from local electronics and plating manufacturers.

RICHMOND, Va., March 17, 2026 (GLOBE NEWSWIRE) -- ARKO Corp. (Nasdaq: ARKO), a Fortune 500 company and one of the largest convenience store operators in the United States, today announced that customers have saved more than $3.75 million on fuel since the launch of its Fueling America’s Future campaign. This milestone reflects ARKO’s continued commitment to delivering meaningful value at the pump during a period of rising fuel prices.

NEW YORK and ALBUQUERQUE, N.M., March 17, 2026 (GLOBE NEWSWIRE) -- Empassion Health, Inc., the nation’s largest manager of patients with serious illness, today announced a strategic partnership with Karoo Health Inc, America’s Cardiac Solution®.

Tax season campaign expected to attract new retail partners and expand LinkUp distribution

IRVINE, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Shimmick Corporation (“Shimmick”) (Nasdaq: SHIM), a national leader in complex infrastructure solutions, today announced that it has secured approximately $256 million in new infrastructure projects, advancing the company’s plans to grow within its core expertise of water and electrical infrastructure in key markets of California and Texas.

Updates simplify visitor workflows, accelerate daily operations, and expand enterprise hardware support

Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the signing of an agreement with a leading global preclinical Contract Research Organization (CRO), a recognized expert in biocompatibility and regulatory-compliant testing.

Chief Product & Process Officer Mary Fuzat to Present on Process First Legal Technology Adoption

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the Class A common stock of Snowflake Inc. (“Snowflake” or the “Company”) (NYSE: SNOW) between June 27, 2023 and the close of market on February 28, 2024 (4:00 p.m. EST), inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Trip.com Group Limited (“Trip.com” or the “Company”) (NASDAQ: TCOM) between April 30, 2024 and January 13, 2026, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE: KD) between August 7, 2024 and February 9, 2025, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Beyond Meat, Inc. (“Beyond Meat” or the “Company”) (NASDAQ: BYND) between February 27, 2025 through November 11, 2025, inclusive (collectively, the “Class Period”).

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of monday.com Ltd. (“monday” or the “Company”) (NASDAQ: MNDY) between September 17, 2025 and February 6, 2026, inclusive (the “Class Period”).

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Enphase Energy Inc. (“Enphase” or the “Company”) (NASDAQ: ENPH) between April 22, 2025 and October 28, 2025, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Zynex, Inc. (“Zynex” or the “Company”) (OTC: ZYXIQ) between February 25, 2021 and December 15, 2025, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Paysafe Limited (“Paysafe” or the “Company”) (NYSE: PSFE) between March 4, 2025 and November 12, 2025, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who sold the common stock of Masonite International Corporation (“Masonite” or the “Company”) (Formerly NYSE: DOOR) between June 5, 2023 and February 8, 2024, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Navan, Inc. (“Navan” or the “Company”) (NASDAQ: NAVN) pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s October 31, 2025 initial public offering.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Camping World Holdings, Inc. (“Camping World” or the “Company”) (NYSE: CWH) between April 29, 2025 and February 24, 2026, inclusive (the “Class Period”).

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of BlackRock TCP Capital Corp. (“BlackRock” or the “Company”) (NASDAQ: TCPC) between November 6, 2024 and January 23, 2026, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of PayPal Holdings, Inc. (“PayPal” or the “Company”) (NASDAQ: PYPL) between February 25, 2025 and February 2, 2026, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Oracle Corporation (“Oracle” or the “Company”) (NYSE: ORCL) between June 12, 2025 and December 16, 2025, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of BellRing Brands, Inc. (“BellRing” or the “Company”) (NYSE: BRBR) between November 19, 2024 through August 4, 2025, inclusive (collectively, the “Class Period”).

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the ordinary shares of uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Driven Brands Holdings Inc. (“Driven Brands” or the “Company”) (NASDAQ: DRVN) between May 9, 2023 and February 24, 2026, inclusive (the “Class Period”).

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Plug Power Inc. (“Plug Power” or the “Company”) (NASDAQ: PLUG) between January 17, 2025 and November 13, 2025, inclusive.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of NuScale Power Corporation (“NuScale” or the “Company”) (NYSE: SMR) between May 13, 2025 and November 6, 2025, inclusive.

CERRITOS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designed to engage innate immune pathways and complement established immuno-oncology therapies.

MORRISVILLE, N.C., March 17, 2026 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, today announced the formal launch of its dedicated Pediatrics Department, reinforcing the company’s commitment to advancing pediatric research by reducing the logistical and emotional burden placed on families.

NEEDHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced an additional 12 months of extended follow-up from its study of aglatimagene plus valacyclovir in combination with continued ICI therapy in patients with advanced NSCLC who had an inadequate response to prior ICI treatment. Among the 46 patients who received two administrations of aglatimagene (per-protocol population), 23 patients (50%) remained alive at 24 months. Additionally, 16 patients (35%) survived beyond 30 months, 12 patients (26%) survived beyond 36 months, 11 patients (24%) survived beyond 40 months, and 6 patients (13%) exceeded 50 months of survival. These outcomes represent an improvement from the prior data cut, in which 39% of the patients in the per-protocol population were alive at 24 months, with 10 patients surviving beyond 30 months, 6 patients each beyond 36 and 40 months, and 2 patients beyond 50 months. The extended follow-up further highlights the durability of anti-tumor immunity observed with aglatimagene-based therapy, and the persistence of a long-term survival tail in this difficult-to-treat population. 

New name and identity reflect the company’s evolution into a unified system for performance across mobile user acquisition, retargeting, CTV, and influencer campaigns

RESTON, Va., March 17, 2026 (GLOBE NEWSWIRE) -- As remote identity verification (IDV) becomes the control plane of the global economy — spanning payments, border crossings, telecom activation, and online platforms — the infrastructure behind verification is scaling rapidly. Regula, a global developer of identity verification solutions, now supports over 240 million end users worldwide, up 62% year-over-year. As governments tighten identity rules and fraud becomes more sophisticated, the infrastructure verifying people online is scaling rapidly.

Army Rapid Fielding Exercise Validates the Capabilities of Safe Pro’s Artificial Intelligence Platform for Autonomous Battlefield Assessment and Planning

New tiers and simplified deal motions support scalable, partner-led MDR growth

PARIS and ATLANTA, March 17, 2026 (GLOBE NEWSWIRE) -- Akur8, the leading Global Actuarial AI platform, announced today it has acquired Slope Software, a cloud-native, all-in-one actuarial modeling platform for life insurers and pension firms. The transaction expands Akur8’s offering beyond Property and Casualty (P&C) into the Life and Annuity (L&A) market, marking a pivotal milestone in its mission to serve actuaries worldwide with best-in-class tools and AI applied where they deliver the greatest impact.

SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) -- Meltwater, a global leader in media, social, and consumer intelligence, announced Antony Cousins, VP of Product, has been named to PRWeek’s AI Top 25 list for 2026. The annual list spotlights the biggest communications technology players advancing artificial intelligence across the PR industry. This recognition is Cousins’ third inclusion on the list, having also been recognized in 2023 and 2024.

Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations in Need of Alternatives to Statins in Cardiovascular Risk Management

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Tuesday, March 24, 2026, at 8:30 a.m. EDT to report its fourth quarter and full year 2025 financial results and recent corporate highlights.

Memory-based Small Language Models deployed across virtualized, highly distributed telecommunications networks achieve sub-500ms response times and up to 40x lower operating costs compared to LLMs on centralized deployment

Transparent Foreign Trade serves as the Turkey execution arm of TFTIOR’s Importer of Record model for regulated technology deployments.

The integration enables enterprise teams to activate and optimize Reddit Ads alongside retail media within a governed, AI-powered commerce operating system.

Award-Winning Executive to Drive Platform Innovation Across ISG's Integrated Claims Services

LAS VEGAS, March 17, 2026 (GLOBE NEWSWIRE) -- TON Strategy Company (Nasdaq: TONX), a digital asset treasury company dedicated to holding Toncoin ($TON), will hold a conference call on Tuesday, March 31, 2026 at 9:00 a.m. Eastern time to discuss its financial results for the fourth quarter and full year ended December 31, 2025. Financial results will be issued in a press release prior to the call.

In just one year of use, AnMed achieved a 14.6X ROI and significant time savings while strengthening collaboration with health plan partners

Fourth Quarter Sales Growth of 2.5%; Full Year Growth of 2.0%

Industry veteran with 20 years of design experience in health, fitness and more further strengthens Noom’s product leadership and expertise

The combined technology and expertise of Verity and CIBO are expected to connect farm-level data to fuel production, enabling auditable carbon intensity calculations and streamlined compliance with emerging clean fuel programs.

HONG KONG and NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- K-Tech Solutions Company Limited (NASDAQ: KMRK; “K-Tech”), a Hong Kong-based design house specializing in complex electromechanical products and educational hardware, announced signing a memorandum of understanding with Boardware Intelligence Technology Limited (HKEX: 1204.HK; “Boardware”). K-Tech will act as Boardware’s exclusive hardware development and engineering partner for Boardware’s AI and Brain-Computer Interface (BCI) product platform.

NEWTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced new research findings at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD), taking place March 17-21, in Copenhagen and online. Shared in one oral and two poster presentations, the data showcase efforts to advance AD treatment through three key areas which include: developing enhanced brain delivery (EBD™) methods for sabirnetug by developing bispecific antibodies that additionally target Transferrin receptors to improve drug penetration across the blood-brain barrier; evaluating novel biomarker approaches using NULISAseq™ technology to better monitor treatment responses in the central nervous system; and creating highly selective antibodies that specifically target toxic AβOs while avoiding non-toxic monomeric forms of the protein.